Corona Remedies Limited has announced the availability of the audio recording from its analyst and investor conference call discussing the company's Q2 FY26 financial results. The pharmaceutical company made this disclosure to both BSE Limited and the National Stock Exchange of India Limited on January 5, 2026.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 by making the earnings call audio accessible to stakeholders. This disclosure follows the company's earlier communication dated December 30, 2025, ensuring transparency in financial reporting processes.

Accessibility and Stakeholder Information

The audio recording of the conference call has been made available on the company's official website for easy access by analysts, investors, and other stakeholders. The recording covers discussions on the company's unaudited financial results for both the second quarter and half year periods ended September 30, 2025.

The disclosure was signed by Chetna Dharajiya, who serves as the Company Secretary and Compliance Officer for Corona Remedies Limited. The company trades on BSE Limited under scrip code 544644 and on the National Stock Exchange of India Limited under the symbol CORONA.

Corona Remedies Limited has announced its financial results for Q2 and H1 FY26 through an investor presentation, showcasing strong operational performance and strategic positioning in the Indian pharmaceutical market. The company has demonstrated consistent growth across revenue, profitability, and margin metrics while maintaining its focus on chronic therapeutic segments.

Strong Financial Performance in Q2 & H1 FY26

The company delivered impressive financial results across both quarterly and half-yearly periods. Revenue growth remained robust, supported by strong operational execution and effective brand management strategies.

The company's gross margin remained healthy at 81.0% for both Q2 FY26 and H1 FY26, reflecting efficient cost management and strong pricing power in its product portfolio.

Strategic Market Positioning and Growth Drivers

Corona Remedies has established itself as a significant player in the Indian pharmaceutical market, demonstrating growth rates substantially higher than industry averages. The company achieved 16.8% average annual growth compared to the Indian Pharmaceutical Market (IPM) average of 9.2%, representing 1.82x outperformance.

The company's strategic focus on chronic therapeutic segments has yielded strong results across key therapy areas:

Manufacturing Capabilities and Infrastructure

The company operates state-of-the-art manufacturing facilities with significant installed capacity. Total formulation capacity stands at 1.65 billion units per annum, with additional capacity for 20 million sachets and 10 million bottles annually. The company recently commenced additional commercial production of 400 million tablets at its Gujarat facility on December 22, 2025.

Corona Remedies maintains high quality standards with EU GMP certification for its Ahmedabad plant and has invested in environmental sustainability through solar power installations totaling 1.3 MW at its Bhayla plant, with plans for an additional 4.25 MW solar park.

Balance Sheet Strength and Cash Flow Generation

The company maintains a strong balance sheet with total assets of ₹976.6 crores as of September 2025, compared to ₹929.9 crores in March 2025. Total equity increased to ₹659.7 crores from ₹606.3 crores, reflecting retained earnings growth and financial stability.

Cash flow generation remained robust with net cash from operating activities of ₹113.4 crores in H1 FY26, compared to ₹104.8 crores in H1 FY25. The company's working capital management showed efficiency with controlled inventory levels and optimized receivables.

Brand Portfolio and Market Strategy

Corona Remedies has built a diversified portfolio of 29 brands with revenues exceeding ₹10 crores each, with approximately 72% of revenue coming from its top brands. The company's top five brands include B-29 (VMN), Myoril (Pain/Analgesics), Tricium (Gynaecology), Cortel (Cardiac), and Obimet (Anti-Diabetic).

The company has successfully scaled acquired brands through strategic acquisitions from major pharmaceutical companies including Abbott India Limited, GSK Pharmaceuticals Limited, Sanofi Healthcare India Private Limited, and Bayer Zydus Pharma Private Limited.

Corona Remedies' strong financial performance in Q2 and H1 FY26 demonstrates the effectiveness of its strategic approach to brand building, therapeutic focus, and operational excellence in the competitive Indian pharmaceutical market.